Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Effect of Pirfenidone on the Prescription of Antibiotics and Antitussive Drugs in Patients With Idiopathic Pulmonary Fibrosis: A Post Hoc Exploratory Analysis of Phase III Clinical Trial.
Suzuki A, Sakaguchi H, Sakamoto K, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Sugiyama Y, Kudoh S, Nukiwa T, Miyazawa S, Kondoh Y. Suzuki A, et al. Among authors: nukiwa t. Chest. 2021 Oct;160(4):1372-1376. doi: 10.1016/j.chest.2021.05.058. Epub 2021 Jun 5. Chest. 2021. PMID: 34102142 Free article. Clinical Trial. No abstract available.
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.
Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Among authors: nukiwa t. Respir Res. 2011 Jul 15;12(1):93. doi: 10.1186/1465-9921-12-93. Respir Res. 2011. PMID: 21756364 Free PMC article. Clinical Trial.
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taguchi Y, et al. Among authors: nukiwa t. Respir Investig. 2015 Nov;53(6):279-87. doi: 10.1016/j.resinv.2015.06.002. Epub 2015 Oct 23. Respir Investig. 2015. PMID: 26521105
Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
Ikeda K, Chiba H, Nishikiori H, Azuma A, Kondoh Y, Ogura T, Taguchi Y, Ebina M, Sakaguchi H, Miyazawa S, Suga M, Sugiyama Y, Nukiwa T, Kudoh S, Takahashi H; Pirfenidone Clinical Study Group in Japan. Ikeda K, et al. Among authors: nukiwa t. Respir Res. 2020 Nov 30;21(1):316. doi: 10.1186/s12931-020-01582-y. Respir Res. 2020. PMID: 33256760 Free PMC article. Clinical Trial.
Pirfenidone in idiopathic pulmonary fibrosis.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Among authors: nukiwa t. Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8. Eur Respir J. 2010. PMID: 19996196 Free article. Clinical Trial.
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.
Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Azuma A, et al. Among authors: nukiwa t. Respir Res. 2011 Oct 28;12(1):143. doi: 10.1186/1465-9921-12-143. Respir Res. 2011. PMID: 22035508 Free PMC article. Clinical Trial.
346 results